4.6 Review

International consensus on (ICON) pediatric asthma

期刊

ALLERGY
卷 67, 期 8, 页码 976-997

出版社

WILEY
DOI: 10.1111/j.1398-9995.2012.02865.x

关键词

asthma; children; consensus; guidelines; wheeze

资金

  1. Nestle
  2. MSD
  3. Deviblis (EBT)
  4. MRC Moulton Charitable Foundation
  5. Merck Inc
  6. Astra Zeneca
  7. GlaxoSmithKline
  8. AstraZeneca
  9. Novartis Research
  10. PREDICTA: European Commission [260895]
  11. Swiss National Science Foundation Research
  12. MeDALL: European Commission [261357]
  13. Christine Kuhne-Center for Allergy Research and Education Research
  14. Food Allergy and Anaphylaxis Network
  15. Food Allergy Initiative
  16. NIH
  17. National Peanut Board
  18. SHS
  19. Wallace Research Foundation
  20. Altus Pharmaceuticals
  21. Inspire Pharmaceuticals
  22. National Institutes of Health
  23. NIH [U01]
  24. AAAAI/GlaxoSmithKline
  25. Pharmaxis
  26. Grupo Uriach Pharma
  27. Turkish National Science Foundation
  28. Hacettepe University
  29. GSK
  30. Adamed
  31. SymbioPharm
  32. Airsonett
  33. Forest Pharmaceuticals
  34. Viro Pharma
  35. Novartis
  36. ALA, Pharmaceuticals
  37. National and regional grants for research in our group
  38. Novartis Pharma
  39. MEDA Pharma
  40. CBF LETI
  41. Allergopharma
  42. Inmunotek
  43. UK National Health Service
  44. Aerocrine
  45. Boehringer Ingelheim
  46. Merck
  47. Mundipharma
  48. Nycomed
  49. Pfizer
  50. Teva
  51. Ross
  52. Abbott
  53. Merck Sharp Dohme
  54. Genentech
  55. MedImmune
  56. Thermofisher

向作者/读者索取更多资源

Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate and fine-tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices; however, this goal has not yet been achieved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据